AbbVie and Genentech, a member of the Roche Group, are working closely with the World Health Organization (WHO) and global health authorities to respond to the needs of patients impacted by COVID-19. For more information about what AbbVie and Genentech are doing to address the global COVID-19 crisis, please visit https://www.abbvie.com/coronavirus.html and https://www.gene.com/covid19.

As the number of COVID-19 cases continue to rise around the world, questions are being raised about the impact it may have on the global supply of medicine. AbbVie and Genentech continue to closely monitor manufacturing and supply chain resources around the world to help ensure our patients continue to receive their medicines. AbbVie and Genentech have not studied the use of VENCLEXTA (venetoclax tablets) in patients with COVID-19 nor in patients at risk of contracting COVID-19.

The decision to initiate VENCLEXTA and treatment management of VENCLEXTA therapy is at the discretion of the patient and health care professional, taking into consideration the risks versus benefits for each patient. Fatal and serious infections such as pneumonia and sepsis have occurred in patients treated with VENCLEXTA. Monitor patients closely for signs and symptoms of infection and treat promptly. Withhold VENCLEXTA for Grade 3 and higher infection. Instruct patients to contact their HCP immediately if they develop a fever or any signs of infection.

Concomitant use of VENCLEXTA with a P-gp inhibitor or strong or moderate CYP3A inhibitor may increase VENCLEXTA toxicities, including the risk of tumor lysis syndrome. Concomitant use of VENCLEXTA with a strong CYP3A inhibitor at initiation and during the ramp-up phase in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma is contraindicated.

Please refer to the full VENCLEXTA Prescribing Information for additional information. 

US-VEN-200028